Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042170 | 1.00 | PDE2A (0.33) | PDE2ALMNAMIFGABRA1L3MBTL1 | |
| SCHEMBL27408321 | 0.80 | CYP2D6 (0.35) | PDE2ALMNAGABRA1L3MBTL1DPP4 | |
| SCHEMBL15295377 | 0.80 | CYP3A4 (0.33) | PDE2ADPP4F2TSHR | |
| SCHEMBL30104386 | 0.80 | CYP3A4 (0.33) | PDE2ADPP4F2TSHR | |
| SCHEMBL30104387 | 0.80 | CYP3A4 (0.33) | PDE2ADPP4F2TSHR | |
| SCHEMBL18328138 | 0.72 | PDE2A (0.58) | PDE2ALMNAMIFGABRA1NOS2 | |
| SCHEMBL22042123 | 0.72 | PDE2A (0.58) | PDE2ALMNAMIFGABRA1NOS2 | |
| SCHEMBL13983512 | 0.72 | PDE2A (0.58) | PDE2ALMNAMIFGABRA1NOS2 | |
| SCHEMBL29888907 | 0.72 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL13983511 | 0.72 | PDE2A (0.38) | PDE2ALMNAMIFGABRA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| EP-3896062-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-111285850-A | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020114482-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | 中国科学院上海药物研究所 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | PDE2A 3829/4885LMNA 2811/4885MIF 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.